Venkatesh Locharla Murthy, MD, PhD, FACC
Professor
Univ Michigan Health Systems

Printed as of 11/24/2026

Disclosures

Personal Commercial (18)

Company Name	Relationship Category	Compensation Level	*Topic Area(s)*
Self			
Abbott Laboratories	Stock	Significant (>= $5,000)	*Prevention General Cardiology Invasive CV Angio and Interventions Vascular Medicine*
AbbVie, Inc.	Stock	Significant (>= $5,000)	*General Cardiology*
Amgen	Stock	Significant (>= $5,000)	*Prevention General Cardiology*
Bristol-Myers Squibb	Stock	Significant (>= $5,000)	*General Cardiology Prevention*
Cardinal Health	Stock	Significant (>= $5,000)	*Noninvasive Imaging*
Eli Lilly and Company	Stock	Significant (>= $5,000)	*General Cardiology*
General Electric	Stock	Modest (< $5,000)	*Noninvasive Imaging*
INVIA Medical Imaging Solutions	Consultant Fees/Honoraria	Significant (>= $5,000)	*Noninvasive Imaging*
INVIA Medical Imaging Solutions	Research/Research Grants	Significant (>= $5,000)	*Noninvasive Imaging*
Ionetix	Consultant Fees/Honoraria	Significant (>= $5,000)	*Noninvasive Imaging*
Medtronic	Stock	Significant (>= $5,000)	*Invasive CV Angio and Interventions*
Merck	Stock	Significant (>= $5,000)	*Prevention General Cardiology*
Mylan Laboratories	Stock	Modest (< $5,000)	*General Cardiology Prevention*
Pfizer	Stock	Significant (>= $5,000)	*General Cardiology*
Siemens	Research/Research Grants *‡ Investigator initiated research grant*	Significant (>= $5,000)	*Noninvasive Imaging*
Singulex	Stock	Significant (>= $5,000)	*Noninvasive Imaging*
Teva Pharmaceuticals	Stock	Modest (< $5,000)	*Prevention General Cardiology*
Viatris	Stock	Modest (< $5,000)	*Other*

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (1)

Year	Case Title	Represented	Description	Compensation
Self				
2019	Patent infringement	Defendant *† Jubilant DRAXimage*	Infringement of design of Rb-82 infusion system	Significant (>= $5,000)

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 10/6/2025
URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 10/6/2025
URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 10/6/2025
URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 10/6/2025

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.